journal article·2025-08

Highly Stable and Bright NIR‐II AIE Dots for Fluorescence Imaging‐Guided Photothermal Ablation of Endometriosis

Zhihui Huang, Jinju Lin, Xiaojun Wang, Jiqiang Liu, Chunyi Zhou, Qingqing Zhang, Ping Gong, Lintao Cai, Pengfei Zhang, He Zhang, Huashan Zhao

Advanced Healthcare Materials· Volume 14· Issue 21
Publisher page

Abstract

Abstract Endometriosis (EM) is a non‐cancerous disease that exhibits certain tumor‐like properties. While hormonal therapies and surgical excision are standard treatments with proven efficacy in alleviating EM symptoms, they are often accompanied by side effects and a high risk of recurrence after surgery. Therefore, there is an urgent need for non‐invasive imaging and therapeutic strategies to address this condition effectively. In this study, second‐window near‐infrared (NIR‐II, 1000–1700 nm) fluorescence imaging is employed, which offers superior spatial resolution, deeper tissue penetration, reduced light scattering, and minimal tissue autofluorescence, to identify EM lesions using aggregation‐induced emission luminogen dots (AIE dots). The AIE dots exhibited excellent photothermal properties, achieving a photothermal conversion efficiency of 40%. AIE dots efficiently accumulate at the lesion site through the enhanced permeability and retention (EPR) effect and rapidly heat up to 50 °C under 808 nm laser irradiation, facilitating the effective ablation of EM lesions. Histological analysis, including hematoxylin and eosin (HE) staining and immunofluorescence staining, confirmed notable reduction of the EM lesions, indicating effective inhibition of lesion progression. This strategy highlights the potential of NIR‐II fluorescence‐guided photothermal therapy as a promising non‐invasive approach for both the diagnosis and treatment of EM.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Quantum Dots Synthesis And Properties · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center of Obstetrics and Gynecology Peking University Shenzhen Hospital Shenzhen 518036 P. R. China

Institute of Obstetrics and Gynecology Shenzhen PKU‐HKUST Medical Center Shenzhen 518036 P. R. China

Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecologic Diseases Shenzhen 518036 P. R. China

Guangdong Key Laboratory of Nanomedicine CAS‐HK Joint Lab of Biomaterials CAS Key Laboratory of Biomedical Imaging Science and System Institute of Biomedicine and Biotechnology Shenzhen Institutes of Advanced Technology (SIAT) Chinese Academy of Sciences Shenzhen 518055 P. R. China

Department of Ophthalmology, Beijing Chaoyang Hospital Capital Medical University Beijing P. R. China

China Railway Lanzhou Group Co., Ltd Lanzhou 518024 P. R. China

Stem Cell & Regenerative Medicine Consortium, School of Biomedical Sciences, LKS Faculty of Medicine The University of Hong Kong, 5/F, Jockey Club Building for Interdisciplinary Research 5 Sassoon Road Hong Kong P. R. China

Centre for Translational Stem Cell Biology 17 W Science Park Hong Kong SAR P. R. China

Sino‐Euro Center of Biomedicine and Health Shenzhen 518024 P. R. China

Department of Pathophysiology College of Basic Medical Sciences Dalian Medical University Dalian 116044 P. R. China

Funding

Shenzhen Science and Technology Innovation Program · National Key Research and Development Program of China

References (50)

Show source-provided references
1. 10.1016/S0140-6736(04)17403-510.1016/S0140-6736(04)17403-5 ↗
2. Horne A. W. · BMJ · 2022 · 379
3. 10.1007/s11154-021-09666-w10.1007/s11154-021-09666-w ↗
4. 10.1016/j.molmed.2018.07.00410.1016/j.molmed.2018.07.004 ↗
5. 10.1177/193371911876625610.1177/1933719118766256 ↗
6. 10.2174/157340481366617030616344810.2174/1573404813666170306163448 ↗
7. 10.1038/nrendo.2013.25510.1038/nrendo.2013.255 ↗
8. 10.1002/adfm.20231590710.1002/adfm.202315907 ↗
9. 10.1146/annurev-pathmechdis-012419-03265410.1146/annurev-pathmechdis-012419-032654 ↗
10. 10.1126/scitranslmed.abq585810.1126/scitranslmed.abq5858 ↗
11. 10.1002/smll.20220769410.1002/smll.202207694 ↗
12. 10.1002/smll.20200497510.1002/smll.202004975 ↗
13. 10.1002/smll.20190693610.1002/smll.201906936 ↗
14. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
15. 10.1039/D0CS00215A10.1039/D0CS00215A ↗
16. 10.1038/s41565-024-01618-010.1038/s41565-024-01618-0 ↗
17. 10.1002/INMD.2023003810.1002/INMD.20230038 ↗
18. 10.1021/acsnano.3c0089110.1021/acsnano.3c00891 ↗
19. 10.1002/adma.20210059910.1002/adma.202100599 ↗
20. 10.1039/C7CS00522A10.1039/C7CS00522A ↗
21. 10.1117/1.JBO.22.8.08090110.1117/1.JBO.22.8.080901 ↗
22. 10.1002/adhm.20230345110.1002/adhm.202303451 ↗
23. 10.1002/advs.20240977810.1002/advs.202409778 ↗
24. 10.1002/smll.20160327010.1002/smll.201603270 ↗
25. 10.1002/smll.20210780810.1002/smll.202107808 ↗
26. 10.1002/adma.20110014010.1002/adma.201100140 ↗
27. 10.1039/C4CS00014E10.1039/C4CS00014E ↗
28. 10.1038/nnano.2015.25110.1038/nnano.2015.251 ↗
29. 10.1002/agt2.62010.1002/agt2.620 ↗
30. 10.1021/accountsmr.0c0011410.1021/accountsmr.0c00114 ↗
31. 10.1021/cbmi.3c0005610.1021/cbmi.3c00056 ↗
32. 10.1002/adma.20240966110.1002/adma.202409661 ↗
33. 10.1002/anie.20200704010.1002/anie.202007040 ↗
34. 10.1002/INMD.2024004810.1002/INMD.20240048 ↗
35. 10.1021/jacs.0c0719310.1021/jacs.0c07193 ↗
36. 10.1038/nmat447610.1038/nmat4476 ↗
37. 10.1002/adma.20110496410.1002/adma.201104964 ↗
38. 10.1002/adhm.20220115810.1002/adhm.202201158 ↗
39. 10.1039/D0CS00664E10.1039/D0CS00664E ↗
40. 10.1039/C9MH00660E10.1039/C9MH00660E ↗
41. 10.1002/agt2.26310.1002/agt2.263 ↗
42. 10.1039/b105159h10.1039/b105159h ↗
43. 10.1002/adma.20200880210.1002/adma.202008802 ↗
44. 10.1002/adma.20240647410.1002/adma.202406474 ↗
45. 10.1021/jacs.3c0862710.1021/jacs.3c08627 ↗
46. 10.1016/j.lfs.2009.03.01510.1016/j.lfs.2009.03.015 ↗
47. 10.1002/smll.20190693610.1002/smll.201906936 ↗
48. Pelch K. E. · J Vis Exp · 2012 · 6
49. 10.1039/C9TB00089E10.1039/C9TB00089E ↗
50. 10.1038/nri242310.1038/nri2423 ↗